血清糖链抗原_(19-9)和糖链抗原_(242)诊断胰腺癌的临床价值

目的探讨血清糖链抗原199(CA199)和糖链抗原242(CA242)测定对胰腺癌的诊断价值。方法回顾性分析2002年4月～2005年9月间我院胰腺癌住院患者43例,按病情分为早期胰腺癌组(A组)10例和晚期胰腺癌组(B组)33例,应用放免法进行血清CA199和CA242的检测,并与同期住院的54例胰腺良性疾病患者血清CA199和CA242水平进行比较。结果胰腺癌患者血清CA199和CA242的测定值和阳性率均显著高于胰腺良性疾病患者(P<0.01),两种肿瘤标记物很少在良性患者中升高,假阳性率CA199为7.4%,CA242为5.6%。且晚期胰腺癌患者血清CA199和CA242的测定值和阳性率均显著高于早期胰腺癌患者。结论血清CA199和CA242测定对胰腺癌的诊断具有一定的临床价值,并可作为胰腺良恶性疾病鉴别和胰腺癌严重程度评判的一个重要参考指标。

The clinical value of tumor marker CA19-9 and CA242 in pancreatic cancer

Objective To investigate the value of CA19-9 and CA 242 in the diagnosis of the pancreatic cancer.Methods 43 patients (from April 2002 to September 2005)with pancreatic cancer in our hospital were divided into two groups (group A and group B) according to the patients’ condition; the levels of CA 19-9 and CA 242 of the patients were measured by immunoradiometric assay. 54 patients with benign pancreatic diseases were chosen as control group, the data were analyzed retrospectively.Results The measured value and positive rate of CA 19-9 and CA 242 in malignant group were obviously higher than those in benign group (P<0.01). The two tumor markers rarely elevated in patients with benign diseases (false positive rate of CA 19-9 was 7.4%,CA 242 was 5.6%).The levels of the two tumor markers and positive rate at late stage were higher than those at early stage.Conclusion CA19-9 and CA242 are valuable tumor markers in the diagnosis of pancreatic cancer, they have important clinical value for the differential diagnosis of pancreatic diseases.